gabexate has been researched along with Cancer of the Urinary Tract in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, H | 1 |
| Ishikawa, S | 1 |
| Rinsho, K | 1 |
| Yazaki, T | 1 |
| Kanoh, S | 1 |
| Koiso, K | 1 |
| Uchida, K | 1 |
| Iizumi, T | 1 |
| Takeshima, H | 1 |
| Umeyama, T | 1 |
1 other study available for gabexate and Cancer of the Urinary Tract
| Article | Year |
|---|---|
[Clinical study on DIC in urological malignancies].
Topics: Aged; Disseminated Intravascular Coagulation; Female; Gabexate; Guanidines; Heparin; Humans; Male; M | 1985 |